Taurultam
Based on 1 Customer Validation
Taurultam is the major active hydrolytic metabolite of Taurolidine (HY-W011522), which selectively activates hTRPA1 to trigger effects in sensory neurons. Taurultam exhibits activity against SARS-CoV-2 variants, influenza A viruses (H1N1, H3N2) and influenza B viruses. Taurultam induces mild tracheal sensory nerve stimulation and CGRP release in mice. Taurultam can be used in studies related to SARS-CoV-2 infection, influenza virus infection, and co-infection with SARS-CoV-2 and influenza A virus.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 38668-01-8
- Formel: C3H8N2O2S
- Molecular Weight:136.17
-
Speicherung:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Taurultam (100 μM-10 mM; 20 seconds) selectively activates HEK293 cells transfected with hTRPA1 in a concentration-dependent manner, and significant calcium influx is observed at concentrations ≥ 100 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Taurultam (140 mg/kg/day; i.p.; daily; 5 days) promotes body weight recovery, reduces lung injury, and lowers viral loads in 4-week-old female golden hamsters infected with SARS-CoV-2 BA.2 strain[1].
Taurultam (200 mg/kg/day; i.p.; daily; 5 days) reduces lung index and viral loads in female BALB/c mice infected with SARS-CoV-2 Omicron BA.2 strain[1].
Taurultam (200 mg/kg/day; i.p.; daily; 5 days) reduces lung index and viral loads in female BALB/c mice infected with SARS-CoV-2 Omicron BF.7 strain[1].
Taurultam (200 mg/kg/day; i.p.; daily; 5 days) reduces lung index and viral loads in female C57BL/6N mice infected with SARS-CoV-2 Omicron BF.7 strain[1].
Taurultam (200 mg/kg/day; i.p.; daily; 5 days) reduces lung index and viral loads in female BALB/c mice infected with SARS-CoV-2 Omicron XBB 1.9.1 strain[1].
Taurultam (200 mg/kg/day; i.p.; daily; 5 days) mitigates body weight loss, improves survival, and reduces lung injury in 8-week-old female BALB/c mice infected with a lethal dose of influenza A H1N1-UI182 virus[1].
Taurultam (200 mg/kg/day; i.p.; daily; 5 days) mitigates body weight loss and reduces lung injury in 8-week-old female BALB/c mice infected with a nonlethal dose of influenza B IBV/S9-MD virus[1].
Taurultam (200 mg/kg/day; i.p.; daily; 5 days) delays death, reduces lung injury, and lowers viral loads of both SARS-CoV-2 and influenza A H1N1-UI182 in female BALB/c mice with viral coinfection[1].
Taurultam (140 mg/kg/day; i.p.; daily; 5 days) mitigates body weight loss and reduces lung injury in 4-week-old female golden hamsters with SARS-CoV-2 Omicron BF.7 and influenza A H1N1-UI182 coinfection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 8-9 months old, challenged with 2000 PFU of SARS-CoV-2/C57MA14 via nasal drop)[1]
-
Dosage:200 mg/kg/day
-
Administration:i.p.; daily; 5 days
-
Result:Improved survival rate from 14.28% to 42.86%.
Mitigated body weight loss.
Reduced patchy lung surface hemorrhage, decreased lung index, reduced inflammatory cell infiltration, hemorrhage, alveolar wall thickening, and viral NP protein expression in lung tissue.
Significantly reduced viral RNA copy numbers in lung tissues and turbinates.
-
Animal Model:Golden hamster (female, 4 weeks old, challenged with 10000 PFU of SARS-CoV-2 BA.2 strain via nasal drop)[1]
-
Dosage:140 mg/kg/day
-
Administration:i.p.; daily; 5 days
-
Result:Promoted body weight recovery.
Ameliorated lung hemorrhage and pathological damage.
Decreased lung index.
Reduced viral RNA copy numbers in nasal lavage fluid, lung tissues, turbinates, and trachea.
-
Animal Model:BALB/c (female, 8-9 months old, challenged with SARS-CoV-2 Omicron BA.2 strain via nasal drop)[1]
-
Dosage:200 mg/kg/day
-
Administration:i.p.; daily; 5 days
-
Result:Decreased lung index at 3 and 5 dpi.
Reduced viral RNA copy numbers in lung tissues and turbinates at 3 and 5 dpi.
-
Animal Model:BALB/c (female, 8-9 months old, challenged with SARS-CoV-2 Omicron BF.7 strain via nasal drop)[1]
-
Dosage:200 mg/kg/day
-
Administration:i.p.; daily; 5 days
-
Result:Decreased lung index at 5 dpi.
Reduced viral RNA copy numbers in lung tissues and turbinates at 3 and 5 dpi.
-
Animal Model:C57BL/6N (female, 8-9 months old, challenged with SARS-CoV-2 Omicron BF.7 strain via nasal drop)[1]
-
Dosage:200 mg/kg/day
-
Administration:i.p.; daily; 5 days
-
Result:Decreased lung index at 3 and 5 dpi.
Reduced viral RNA copy numbers in lung tissues and turbinates at 3 and 5 dpi.
-
Animal Model:BALB/c (female, 8-9 months old, challenged with SARS-CoV-2 Omicron XBB 1.9.1 strain via nasal drop)[1]
-
Dosage:200 mg/kg/day
-
Administration:i.p.; daily; 5 days
-
Result:Decreased lung index at 3 and 5 dpi.
Reduced viral RNA copy numbers in lung tissues and turbinates at 3 and 5 dpi.
-
Animal Model:BALB/c (female, 8 weeks old, challenged with 10×LD50 of influenza A H1N1-UI182 virus via nasal drop)[1]
-
Dosage:200 mg/kg/day
-
Administration:i.p.; daily; 5 days
-
Result:Mitigated body weight loss.
Improved survival rate.
Reduced lung surface hemorrhages, decreased lung index, and reduced lung pathological damage and pathology scores.
-
Animal Model:BALB/c (female, 8 weeks old, challenged with nonlethal dose of influenza B IBV/S9-MD virus via nasal drop)[1]
-
Dosage:200 mg/kg/day
-
Administration:i.p.; daily; 5 days
-
Result:Mitigated body weight loss.
Reduced lung surface hemorrhages, decreased lung index, and reduced lung pathological damage and pathology scores.
-
Animal Model:BALB/c (female, 8-9 months old, challenged with 1000 PFU influenza A H1N1-UI182 and 2000 PFU SARS-CoV-2/C57MA14 via nasal drop)[1]
-
Dosage:200 mg/kg/day
-
Administration:i.p.; daily; 5 days
-
Result:Delayed death of infected mice.
Improved lung pathological damage and reduced lung pathology scores.
Decreased viral RNA copy numbers of both SARS-CoV-2 and H1N1-UI182 in turbinates at 2 and 4 dpi.
Reduced viral NP protein expression of both viruses at 2 and 4 dpi.
-
Animal Model:Golden hamster (female, 4 weeks old, challenged with 1000 PFU influenza A H1N1-UI182 and 1000 PFU SARS-CoV-2 Omicron BF.7 via nasal drop)[1]
-
Dosage:140 mg/kg/day
-
Administration:i.p.; daily; 5 days
-
Result:Mitigated body weight loss.
Reduced pulmonary hemorrhage and lung pathological damage.
Decreased lung index and lung pathology scores.
Chemical Information
-
CAS. Nr. 38668-01-8
-
Appearance Solid
-
Molecular Weight 136.17
-
Formel C3H8N2O2S
-
Color White to off-white
-
SMILES
O=S1(NCNCC1)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (615 KB)
- English - EN (615 KB)
- Français - FR (615 KB)
- Deutsch - DE (615 KB)
- Norwegian - NO (615 KB)
- Español - ES (615 KB)
- Swedish - SV (615 KB)
- Italian - IT (615 KB)
- Korean - KR (615 KB)
- Portuguese - PT (615 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Luo R, et al. Taurultam shows antiviral activity against SARS-CoV-2 and influenza virus. BMC microbiology. 2025 May 15;25(1):292. [Content Brief]
[2]. Kichko TI, et al. Taurolidine and congeners activate hTRPA1 but not hTRPV1 channels and stimulate CGRP release from mouse tracheal sensory nerves. Pharmacology research & perspectives. 2016 Feb;4(1):e00204. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Taurultam Related Classifications
HY-136820 Related Classifications
Powered by Bioz